Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962681 | 0.89 | POLB (0.77) | POLBKMT2ALMNAHSD17B10MEN1 | |
| SCHEMBL7661631 | 0.88 | RAB9A (0.73) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL7661191 | 0.87 | RAB9A (0.72) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL1001171 | 0.87 | RAB9A (0.72) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL7664126 | 0.86 | KMT2A (0.57) | POLBKMT2ALMNAHSD17B10MEN1 | |
| SCHEMBL7656561 | 0.86 | KMT2A (0.65) | POLBKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL7662928 | 0.85 | SMN1; SMN2 (0.70) | POLBKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL7656637 | 0.84 | KMT2A (0.73) | POLBKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL7662995 | 0.84 | KMT2A (0.60) | POLBKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL7657082 | 0.84 | KMT2A (0.63) | POLBKMT2ALMNAMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2079525-A1 | CALCIUM RECEPTOR MODULATING AGENTS | Amgen Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355633-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2000058277-A1 | ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | POLB 4823/4885KMT2A 4786/4885LMNA 3345/4885 |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | FSHR, GNRHR, LHCGR | POLB 3896/4885KMT2A 1116/4885LMNA 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.